Association between hypertensive disorders of pregnancy and later risk of cardiomyopathy

JAMA - Journal of the American Medical Association

Volumn 315, Issue 10, 2016, Pages 1026-1033

  Behrens, Ida ^a   Basit, Saima ^a   Lykke, Jacob Alexander ^b   Ranthe, Mattis Flyvholm ^a   Wohlfahrt, Jan ^a   Bundgaard, Henning ^b   Melbye, Mads ^c,d   Boyd, Heather A ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; OUTCOME ASSESSMENT; PERINATAL PERIOD; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STILLBIRTH; CARDIOMYOPATHIES; HYPERTENSION, PREGNANCY-INDUCED; MIDDLE AGED; PRE-ECLAMPSIA; PREGNANCY; PROPORTIONAL HAZARDS MODEL; PUERPERIUM; REGISTER; RISK; TIME; TIME FACTOR; YOUNG ADULT;

ADULT; CARDIOMYOPATHIES; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MIDDLE AGED; POSTPARTUM PERIOD; PRE-ECLAMPSIA; PREGNANCY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK; TIME FACTORS; YOUNG ADULT;

EID: 84960938333     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.1869     Document Type: Article

References (33)

1. American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-1131.
2. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7.
3. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376 (9741):631-644.
4. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62(18):1715-1723.
5. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58(7):659-670.
6. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006;368(9536):687-693.
7. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013;28(1):1-19.
8. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156(5):918-930.
9. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53(6):944-951.
10. Wikström A-K, Haglund B, Olovsson M, Lindeberg SN. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG. 2005;112(11):1486-1491.
11. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.
12. Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension. 2011;58(4):709-715.
13. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension. 2011;57 (1):85-93.
14. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123(24):2856-2869.
15. Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333-338.
16. Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97-104.
17. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491): 565.
18. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270-276.
19. Lange T, Vansteelandt S, Bekaert M. A simple unified approach for estimating natural direct and indirect effects. Am J Epidemiol. 2012;176(3):190-195.
20. Mosca L, Benjamin EJ, Berra K, et al; American Heart Association. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011; 57(12):1404-1423.
21. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;77(1):147-160.
22. Melchiorre K, Sharma R, Thilaganathan B. Cardiovascular implications in preeclampsia: an overview. Circulation. 2014;130(8):703-714.
23. Melchiorre K, Thilaganathan B. Maternal cardiac function in preeclampsia. Curr Opin Obstet Gynecol. 2011;23(6):440-447.
24. Melchiorre K, Sutherland G, Sharma R, Nanni M, Thilaganathan B. Mid-gestational maternal cardiovascular profile in preterm and term pre-eclampsia: a prospective study. BJOG. 2013;120 (4):496-504.
25. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-683.
26. Levine RJ, Lam C, Qian C, et al; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992-1005.
27. Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17(1):3-18.
28. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol. 2004;190(6):1541-1547.
29. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122(5): 478-487.
30. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125(7):911-919.
31. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: diagnosis and management of preeclampsia and eclampsia.Obstet Gynecol. 2002;99(1):159-167.
32. Klemmensen AK, Olsen SF, Osterdal ML, Tabor A. Validity of preeclampsia-related diagnoses recorded in a national hospital registry and in a postpartum interview of the women. Am J Epidemiol. 2007;166(2):117-124.
33. Wilkins-Haug L, Celi A, Thomas A, Frolkis J, Seely EW. Recognition by women's health care providers of long-term cardiovascular disease risk after preeclampsia. Obstet Gynecol. 2015;125(6): 1287-1292.